What is VRD disease?

What is VRD disease?

Von Recklinghausen’s disease (VRD) is a genetic disorder characterized by the growth of tumors on the nerves. The disease can also affect the skin and cause bone deformities. There are three forms of VRD: neurofibromatosis type 1 (NF1) neurofibromatosis type 2 (NF2)

Which of the following is a characteristic of von Recklinghausen syndrome?

Neurofibromatosis 1 (NF1), also called von Recklinghausen’s disease, is a genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas) and areas of abnormal skin color (pigmentation).

What causes neurofibromatosis?

Neurofibromatosis is caused by genetic defects (mutations) that either are passed on by a parent or occur spontaneously at conception. The specific genes involved depend on the type of neurofibromatosis: NF1 . The NF1 gene is located on chromosome 17.

What is iris hamartoma?

A hamartoma is defined as a benign tumor or nodular growth that is composed of proliferating mature histologically normal cells that normally reside at the affected tissue. In ophthalmic jargon, iris hamartomas traditionally refer to Lisch nodules which are encountered in patients with neurofibromatosis type 1 (NF1).

How long can you live with NF?

If there are no complications, the life expectancy of people with NF is almost normal. With the right education, people with NF can live a normal life. Although mental impairment is generally mild, NF1 is a known cause of attention deficit hyperactivity disorder. Learning disabilities are a common problem.

Can NF1 be prevented?

Can neurofibromatosis be prevented or avoided? You cannot avoid NF. You can have genetic testing to see if you carry the gene.

How do you control neurofibroma?

Neurofibroma treatment usually involves monitoring or surgery.

  1. Monitoring. Your doctor may recommend observation of a tumor if it’s in a place that makes removal difficult or if it’s small and causes no problems.
  2. Surgery to remove the tumor.
  3. Clinical trials.

author

Back to Top